We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

UNITY Biotechnology Inc (UBX) USD0.0001

Sell:$0.95 Buy:$0.96 Change: $0.0101 (1.04%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.95
Buy:$0.96
Change: $0.0101 (1.04%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.95
Buy:$0.96
Change: $0.0101 (1.04%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.

Contact details

Address:
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 4161192
Website:
https://unitybiotechnology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
UBX
ISIN:
US91381U2006
Market cap:
$16.85 million
Shares in issue:
16.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Anirvan Ghosh
    Chief Executive Officer, Director
  • Lynne Sullivan
    Chief Financial Officer, Head - Corporate Development
  • Alexander Nguyen
    Chief Legal Officer and Head - Operations
  • Alicia Tozier
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.